Literature DB >> 32200519

Dual RAAS inhibition and cardiorenal disease: is enough really enough?

Claudio Borghi1, Maddalena Veronesi2, Stefano Bacchelli2, Daniela Degli Esposti2.   

Abstract

Entities:  

Year:  2020        PMID： 32200519     DOI： 10.1007/s11739-020-02313-3

Source DB:  PubMed          Journal:  Intern Emerg Med        ISSN： 1828-0447            Impact factor:   3.397


× No keyword cloud information.
  10 in total

Review 1.  Direct renin inhibition: from pharmacological innovation to novel therapeutic opportunities.

Authors:  Massimo Volpe; Roberto Pontremoli; Claudio Borghi
Journal:  High Blood Press Cardiovasc Prev       Date:  2011-09-01

2.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 3.  Angiotensin-Converting Enzyme Inhibitors in Hypertension: To Use or Not to Use?

Authors:  Franz H Messerli; Sripal Bangalore; Chirag Bavishi; Stefano F Rimoldi
Journal:  J Am Coll Cardiol       Date:  2018-04-03       Impact factor: 24.094

Review 4.  Effects of blood pressure lowering on outcome incidence in hypertension: 4. Effects of various classes of antihypertensive drugs--overview and meta-analyses.

Authors:  Costas Thomopoulos; Gianfranco Parati; Alberto Zanchetti
Journal:  J Hypertens       Date:  2015-02       Impact factor: 4.844

5.  Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial.

Authors:  John J V McMurray; Jan Ostergren; Karl Swedberg; Christopher B Granger; Peter Held; Eric L Michelson; Bertil Olofsson; Salim Yusuf; Marc A Pfeffer
Journal:  Lancet       Date:  2003-09-06       Impact factor: 79.321

Review 6.  Role of the Renin-Angiotensin-Aldosterone System and Its Pharmacological Inhibitors in Cardiovascular Diseases: Complex and Critical Issues.

Authors:  Claudio Borghi; Francesco Rossi
Journal:  High Blood Press Cardiovasc Prev       Date:  2015-09-24

7.  Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both.

Authors:  Marc A Pfeffer; John J V McMurray; Eric J Velazquez; Jean-Lucien Rouleau; Lars Køber; Aldo P Maggioni; Scott D Solomon; Karl Swedberg; Frans Van de Werf; Harvey White; Jeffrey D Leimberger; Marc Henis; Susan Edwards; Steven Zelenkofske; Mary Ann Sellers; Robert M Califf
Journal:  N Engl J Med       Date:  2003-11-10       Impact factor: 91.245

8.  2018 Practice Guidelines for the management of arterial hypertension of the European Society of Hypertension and the European Society of Cardiology: ESH/ESC Task Force for the Management of Arterial Hypertension.

Authors:  Bryan Williams; Giuseppe Mancia; Wilko Spiering; Enrico Agabiti Rosei; Michel Azizi; Michel Burnier; Denis Clement; Antonio Coca; Giovanni De Simone; Anna Dominiczak; Thomas Kahan; Felix Mahfoud; Josep Redon; Luis Ruilope; Alberto Zanchetti; Mary Kerins; Sverre Kjeldsen; Reinhold Kreutz; Stephane Laurent; Gregory Y H Lip; Richard McManus; Krzysztof Narkiewicz; Frank Ruschitzka; Roland Schmieder; Evgeny Shlyakhto; Konstantinos Tsioufis; Victor Aboyans; Ileana Desormais
Journal:  J Hypertens       Date:  2018-12       Impact factor: 4.844

Review 9.  Effects of dual inhibition of renin-angiotensin-aldosterone system on cardiovascular and renal outcomes: balancing the risks and the benefits.

Authors:  Giuliano Tocci; Barbara Citoni; Vivianne Presta; Giovanna Leoncini; Francesca Viazzi; Barbara Bonino; Massimo Volpe; Roberto Pontremoli
Journal:  Intern Emerg Med       Date:  2019-12-21       Impact factor: 3.397

10.  Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.

Authors:  Erminia Donnarumma; Murtuza J Ali; Amanda M Rushing; Amy L Scarborough; Jessica M Bradley; Chelsea L Organ; Kazi N Islam; David J Polhemus; Stefano Evangelista; Giuseppe Cirino; J Stephen Jenkins; Rajan A G Patel; David J Lefer; Traci T Goodchild
Journal:  J Am Heart Assoc       Date:  2016-07-05       Impact factor: 5.501
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.